《大行報告》美銀美林舜宇(02382.HK)毛利率或較預期佳升目標價至110元
美銀美林發表報告指,舜宇光學(02382.HK)將於8月中旬公布今年上半年業績,相信焦點將會是毛利率方面。該行預期,在收益率改善及高端鏡頭模組產量提升的背景下,舜宇上半年毛利率料為17.3%,可較預期為佳。純利方面,該行及市場預期舜宇上半年純利約為12億元人民幣,按年大致持平。
該行表示,輕微調升對舜宇今年至2021年的每股盈利預測2%,以反映更佳的毛利輪廓,股份目標價由95元升至110元,此相當預測2019年下半年至2020年上半年綜合市盈率25倍,重申對其「買入」投資評級。
美銀美林表示,繼續喜好舜宇在智能手機光學市場的佔有率增長,以及其在車載鏡頭板塊有強大影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.